Basic and clinical studies on fleroxacin in urological infections

We studied the antibacterial activity and clinical utility of fleroxacin, a new oral fluoroquinolone, in urological infections. 1. Antibacterial activity: the MICs of fleroxacin against clinical isolates (185 strains of 12 species) from urinary tract infections, were compared with those of ofloxacin (OFLX) and norfloxacin (NFLX). Except against P.aeruginosa, the overall antibacterial activity of fleroxacin was excellent and similar to that of NFLX. 2. Clinical efficacy: the overall clinical efficacy according to the criteria of the Japanese UTI Committee was 100%(1/1) in acute uncomplicated cystitis and 75.6%(31/41) in chronic complicated UTI. Bacteriologically, 36 of 45 strains (80.0%) were eradicated. 3. Side effects: facial hot flushes were noted in one patient, but the symptom was mild and transient. With regard to laboratory findings, slight and transient elevations of GOT and GPT and of BUN and s-Cr were seen in one patient.